Metallothionein Protects Islets from Hypoxia and Extends Islet Graft Survival by Scavenging Most Kinds of Reactive Oxygen Species

Abstract

Islet transplantation is a promising therapy for Type 1 diabetes, but many attempts have failed due to early graft hypoxia or immune rejection, which generate reactive oxygen species (ROS). In the current study, we determined that transgenic overexpression of the antioxidant metallothionein (MT) in pancreatic beta cells provided broad resistance to oxidative stress by scavenging most kinds of ROS including H2O2, peroxynitrite radical released from streptozotocin, 3-morpholinosydnonimine (SIN-1), and superoxide radical produced by xanthine/xanthine oxidase. MT also reduced nitric oxide-induced beta cell death. A direct test of hypoxia/reperfusion sensitivity was made by exposing FVB and MT islets to hypoxia (1% O2). MT markedly reduced ROS production and improved islet cell survival. Because MT protected beta cells from a broad spectrum of ROS and from hypoxia, we considered it to be an ideal candidate for improving islet transplantation. We first tested syngeneic transplantation by implanting islets under the kidney capsule of the same strain, FVB mice, thereby eliminating the immune rejection component. Under these conditions, MT islets maintained much greater was MT transgenic and FVB islets under the kidney capsule of that to We that MT islets the of of MT was due to from ROS an of radical was much in MT in FVB of that the of MT have from hypoxia or that a broad spectrum antioxidant islets from ROS that produced the early of islet transplantation. Islet transplantation is a promising therapy for Type 1 diabetes, but many attempts have failed due to early graft hypoxia or immune rejection, which generate reactive oxygen species (ROS). In the current study, we determined that transgenic overexpression of the antioxidant metallothionein (MT) in pancreatic beta cells provided broad resistance to oxidative stress by scavenging most kinds of ROS including H2O2, peroxynitrite radical released from streptozotocin, 3-morpholinosydnonimine (SIN-1), and superoxide radical produced by xanthine/xanthine oxidase. MT also reduced nitric oxide-induced beta cell death. A direct test of hypoxia/reperfusion sensitivity was made by exposing FVB and MT islets to hypoxia (1% O2). MT markedly reduced ROS production and improved islet cell survival. Because MT protected beta cells from a broad spectrum of ROS and from hypoxia, we considered it to be an ideal candidate for improving islet transplantation. We first tested syngeneic transplantation by implanting islets under the kidney capsule of the same strain, FVB mice, thereby eliminating the immune rejection component. Under these conditions, MT islets maintained much greater was MT transgenic and FVB islets under the kidney capsule of that to We that MT islets the of of MT was due to from ROS an of radical was much in MT in FVB of that the of MT have from hypoxia or that a broad spectrum antioxidant islets from ROS that produced the early of islet transplantation. of pancreatic islets is considered to be of the most for Type 1 islet transplantation the in of for 1 of transplantation therapy is by the for and in that many islets the of transplantation islet and many beta cells to the of islets to is an of pancreatic islet of the of islets a is to islet graft the early of transplantation. to to early graft oxygen species reactive oxygen streptozotocin, of reactive oxygen streptozotocin, of in early islet graft and immune islet to that generate nitric and In the islet by of nitric released from or In the graft from an of transplantation. the islet graft is In islets oxygen and the of is by a of to ROS in of ROS pancreatic islets have in in islet transplantation of islets islets or beta cell to ROS markedly beta cell and in beta cell death. cell pancreatic beta cells to by ROS is islet cells and of ROS that early islet graft be by antioxidant and have transgenic overexpression of a antioxidant from the superoxide radical by of was to islet graft by in we that overexpression of the failed to in syngeneic islet test beta cell be improved by species of have antioxidant In of or provided superoxide and nitric of of superoxide and in islets antioxidant that was by scavenging species of we that a of islet graft be the islets protected by a antioxidant a broad spectrum of ROS scavenging metallothionein is a and that MT to an in and to many MT also a of MT in pancreatic beta produced by or by transgenic to from beta cell and in have that MT is to a of ROS including and nitric it is that MT a broad spectrum of antioxidant in was to test overexpression of a broad spectrum antioxidant improved beta cell MT is first to be a broad spectrum antioxidant in of scavenging many of We that MT islets to hypoxia ROS and reduced cell death. In syngeneic MT markedly improved the of graft and in MT the of transgenic in the FVB pancreatic beta cell overexpression of the MT transgenic was in the of from in the of to and by the and which is by the of of 3-morpholinosydnonimine (SIN-1), and from and by was from to was from was by was from was from was a of the of and islets in the transplantation and in which the of ROS ROS production in islet the islets first cells by in and for by of A cell and was to islet cells for by of cells in the cells the islet cells a a of in of islet of ROS or to the the of the of in was a an of and an of production in islets hypoxia was a from the of in the or FVB or MT transgenic islets for by of of islet was an of and an of ROS was from islets an a islets from islet for the in FVB and islets to of a nitric for and was an the islets for in of in a or the was for was the was of for was for was the the and to the in the to islet by FVB and islets in a in a and for or the islet cell was by islet by for cell the of of cells that in ROS production in islets hypoxia for was which a that and in to cell is a to cell of cells In and In FVB islets or transgenic islets of in a for and the was a the of and the of provided an the and was to the islets in of under or hypoxia (1% for the of of was of for a of was for and the was Islet cell was the of to the FVB and islets under kidney capsule in a FVB to a of the of of a and kidney was first a and islets a a and to was an the kidney and the islets of the and the the transplantation to the kidney was by the same by a of the kidney many the graft of the kidney was in for the we an and to the of or was 1 of in the and the for was in a of the of the was from a made FVB or islets under kidney capsule the same the mice, a of to from to for transplantation the to of the a was a of Islet graft was the of from transplantation to the first of of from transplantation and for and In in which kidney was we that of the graft kidney a to for in in in an of and and in and a of by was to the a of and in by and of MT graft and FVB graft from a from 1 to the of by to the of the the was by or and and test to islet graft test was to in islet from and ROS by that the MT protected ROS released by MT many species of beta cells to H2O2, the superoxide radical produced by and and the peroxynitrite radical released from cell ROS production was reduced by the MT to also to nitric by a nitric in we resistance to nitric by in islet and islet cell death. in MT islets to and cell by that MT is to or most of oxide-induced in FVB and MT transgenic islets to for of FVB and MT islets of the in was and in was under and from and that MT and FVB the same and by and to ROS production MT ROS we FVB and MT transgenic islets to is to the that islets to the graft ROS production was of hypoxia and to in the of the hypoxia ROS FVB and MT islets produced ROS to the ROS was greater in FVB islets in MT in ROS improved islet we islet the MT and FVB islets to for and and in islet cell was markedly by hypoxia of MT provided resistance to production in FVB and MT islets to hypoxia for MT reduced ROS production in islet ROS production of islets was under and of that hypoxia ROS in FVB islets that MT ROS FVB of hypoxia was by the in MT transgenic and FVB islets hypoxia FVB and MT islets to hypoxia for and and islet cell was by the under and from that MT from the FVB by that islets the early of transplantation the of MT to hypoxia and be in a transplantation islets FVB to but to immune rejection or MT transgenic islets under kidney and FVB islets under the kidney capsule of the same the graft was for of is a of islet that FVB and MT islet of transplantation. FVB islets MT islets of FVB islets of of FVB and MT islets syngeneic transplantation. islet was of FVB mice, and the of was under and from FVB that the of MT and FVB by also FVB islets or MT transgenic islets under the of FVB islets to in for an of same of MT transgenic islets was for MT islets was to of islet graft that MT in of FVB or MT transgenic islets transplantation. islets under kidney of of was of from FVB islet and MT transgenic islet of MT islet was that of FVB by that the of MT islets was due to from in islet of transplantation was is a for the of in in MT was markedly in FVB islet was by of MT and FVB graft from production in FVB and MT and and and kidney islet from A and of FVB and of MT to of kidney was of in FVB and MT islet from for of graft from and by MT production in islet by the the study, we that overexpression of MT reduced ROS in beta cells to many from ROS islet a nitric or to MT transgenic islets maintained islets syngeneic transplantation. MT islets by transplantation and MT reduced the of in islet of MT was due to from hypoxia due to of immune to many ROS transplantation and the of ROS or to beta cells it is that antioxidant many of ROS most antioxidant in and in the of ROS that and and superoxide is to of the provided by a antioxidant was the that protected islets from but provided from nitric MT broad antioxidant In MT to nitric radical superoxide radical radical and peroxynitrite We that MT was of these ROS in transgenic pancreatic islets and also that MT reduced and produced by nitric is considered to be an of beta cell produced by many of MT most ROS that MT overexpression a test of the of ROS in beta cell produced transplantation and overexpression was to the of by in to an of of improved graft that MT most the produced in the early of to immune rejection of the we that MT protected graft in syngeneic which is in the of immune many that to early graft that hypoxia is Islet an in syngeneic islets is O2). of oxygen islet cell and cell survival. that is a reduced oxygen and the of in and islets Islet to by by the of of cell produced by in hypoxia in the is MT was in ROS and cell produced by Because was from the of ROS have due to hypoxia or have to the of islet of and the islets overexpression of an of immune produced a of graft which was to be due to from immune We that MT produced a or greater of in in a direct of the of the is provided MT is and protected hypoxia, is and was to immune the of these of or the for islet transplantation. the for and islet transplantation. of is an in graft is MT improved islet by to that ROS for islet and be in islet graft of pancreatic islets is considered to be of the most for Type 1 islet transplantation the in of for 1 of transplantation therapy is by the for and in that many islets the of transplantation islet and many beta cells to the of islets to is an of pancreatic islet of the of islets a is to islet graft the early of transplantation. to to early graft oxygen species reactive oxygen streptozotocin, of reactive oxygen streptozotocin, of in early islet graft and immune islet to that generate nitric and In the islet by of nitric released from or In the graft from an of transplantation. the islet graft is In islets oxygen and the of is by a of to ROS in of ROS pancreatic islets have in in islet transplantation of islets islets or beta cell to ROS markedly beta cell and in beta cell death. cell pancreatic beta cells to by ROS is islet cells and of ROS that early islet graft be by antioxidant and have transgenic overexpression of a antioxidant from the superoxide radical by of was to islet graft by in we that overexpression of the failed to in syngeneic islet test beta cell be improved by species of have antioxidant In of or provided superoxide and nitric of of superoxide and in islets antioxidant that was by scavenging species of we that a of islet graft be the islets protected by a antioxidant a broad spectrum of ROS scavenging metallothionein MT is a and that MT to an in and to many MT also a of MT in pancreatic beta produced by or by transgenic to from beta cell and in have that MT is to a of ROS including and nitric it is that MT a broad spectrum of antioxidant in was to test overexpression of a broad spectrum antioxidant improved beta cell MT is first to be a broad spectrum antioxidant in of scavenging many of We that MT islets to hypoxia ROS and reduced cell death. In syngeneic MT markedly improved the of graft and in MT the of transgenic in the FVB pancreatic beta cell overexpression of the MT transgenic was in the of from in the of to and by the and which is by the of of 3-morpholinosydnonimine (SIN-1), and from and by was from to was from was by was from was from was a of the of and islets in the transplantation and in which the of ROS ROS production in islet the islets first cells by in and for by of A cell and was to islet cells for by of cells in the cells the islet cells a a of in of islet of ROS or to the the of the of in was a an of and an of production in islets hypoxia was a from the of in the or FVB or MT transgenic islets for by of of islet was an of and an of ROS was from islets an a islets from islet for the in FVB and islets to of a nitric for and was an the islets for in of in a or the was for was the was of for was for was the the and to the in the to islet by FVB and islets in a in a and for or the islet cell was by islet by for cell the of of cells that in ROS production in islets hypoxia for was which a that and in to cell is a to cell of cells In and In FVB islets or transgenic islets of in a for and the was a the of and the of provided an the and was to the islets in of under or hypoxia (1% for the of of was of for a of was for and the was Islet cell was the of to the FVB and islets under kidney capsule in a FVB to a of the of of a and kidney was first a and islets a a and to was an the kidney and the islets of the and the the transplantation to the kidney was by the same by a of the kidney many the graft of the kidney was in for the we an and to the of or was 1 of in the and the for was in a of the of the was from a made FVB or islets under kidney capsule the same the mice, a of to from to for transplantation the to of the a was a of Islet graft was the of from transplantation to the first of of from transplantation and for and In in which kidney was we that of the graft kidney a to for in in in an of and and in and a of by was to the a of and in by and of MT graft and FVB graft from a from 1 to the of by to the of the the was by or and and test to islet graft test was to in islet from and transgenic in the FVB pancreatic beta cell overexpression of the MT transgenic was in the of from in the of to and by the and which is by the of of 3-morpholinosydnonimine (SIN-1), and from and by was from to was from was by was from was from Islet was a of the of and islets in the transplantation and in which the of ROS ROS production in islet the islets first cells by in and for by of A cell and was to islet cells for by of cells in the cells the islet cells a a of in of islet of ROS or to the the of the of in was a an of and an of ROS production in islets hypoxia was a from the of in the or FVB or MT transgenic islets for by of of islet was an of and an of ROS was from islets an a islets from islet for the in FVB and islets to of a nitric for and was an the islets for in of in a or the was for was the was of for was for was the the and to the in the to islet by In FVB and islets in a in a and for or the islet cell was by islet by for cell the of of cells that in ROS production in islets hypoxia for was which a that and in to cell is a to cell of cells In and In FVB islets or transgenic islets of in a for and the was a the of and the of provided an the and was to the islets in of under or hypoxia (1% for the of of was of for a of was for and the was Islet cell was the of to the FVB and islets under kidney capsule in a FVB to a of the of of a and kidney was first a and islets a a and to was an the kidney and the islets of the and the the transplantation to the kidney was by the same by a of the kidney many the graft of the kidney was in for the we an and to the of or was 1 of in the and the for was in a of the of the was from a made FVB or islets under kidney capsule the same the mice, a of to from to for transplantation the to of the a was a of Islet graft was the of from transplantation to the first of of from transplantation and for and In in which kidney was we that of the graft kidney a to for in in in an of and and in and a of by was to the a of and in by and of MT graft and FVB graft from a from 1 to the of by to the of the the was by or and and test to islet graft test was to in islet from and ROS by that the MT protected ROS released by MT many species of beta cells to H2O2, the superoxide radical produced by and and the peroxynitrite radical released from cell ROS production was reduced by the MT to also to nitric by a nitric in we resistance to nitric by in islet and islet cell death. in MT islets to and cell by that MT is to or most of and to ROS production MT ROS we FVB and MT transgenic islets to is to the that islets to the graft ROS production was of hypoxia and to in the of the hypoxia ROS FVB and MT islets produced ROS to the ROS was greater in FVB islets in MT in ROS improved islet we islet the MT and FVB islets to for and and in islet cell was markedly by hypoxia of MT provided resistance to production in FVB and MT islets to hypoxia for MT reduced ROS production in islet ROS production of islets was under and of that hypoxia ROS in FVB islets that MT ROS FVB of hypoxia was by the in MT transgenic and FVB islets hypoxia FVB and MT islets to hypoxia for and and islet cell was by the under and from that MT from the FVB by that islets the early of transplantation the of MT to hypoxia and be in a transplantation islets FVB to but to immune rejection or MT transgenic islets under kidney and FVB islets under the kidney capsule of the same the graft was for of is a of islet that FVB and MT islet of transplantation. FVB islets MT islets of FVB islets of of FVB and MT islets syngeneic transplantation. islet was of FVB mice, and the of was under and from FVB that the of MT and FVB by also FVB islets or MT transgenic islets under the of FVB islets to in for an of same of MT transgenic islets was for MT islets was to of islet graft that MT in of FVB or MT transgenic islets transplantation. islets under kidney of of was of from FVB islet and MT transgenic islet of MT islet was that of FVB by that the of MT islets was due to from in islet of transplantation was is a for the of in in MT was markedly in FVB islet was by of MT and FVB graft from production in FVB and MT and and and kidney islet from A and of FVB and of MT to of kidney was of in FVB and MT islet from for of graft from and by MT production in islet by the ROS by that the MT protected ROS released by MT many species of beta cells to H2O2, the superoxide radical produced by and and the peroxynitrite radical released from cell ROS production was reduced by the MT to also to nitric by a nitric in we resistance to nitric by in islet and islet cell death. in MT islets to and cell by that MT is to or most of In and to ROS production MT ROS we FVB and MT transgenic islets to is to the that islets to the graft ROS production was of hypoxia and to in the of the hypoxia ROS FVB and MT islets produced ROS to the ROS was greater in FVB islets in MT in ROS improved islet we islet the MT and FVB islets to for and and in islet cell was markedly by hypoxia of MT provided resistance to that islets the early of transplantation the of MT to hypoxia and be in a transplantation islets FVB to but to immune rejection or MT transgenic islets under kidney and FVB islets under the kidney capsule of the same the graft was for of is a of islet that FVB and MT islet of transplantation. FVB islets MT islets of FVB islets of We also FVB islets or MT transgenic islets under the of FVB islets to in for an of same of MT transgenic islets was for MT islets was to of islet graft that MT in that the of MT islets was due to from in islet of transplantation was is a for the of in in MT was markedly in FVB islet was by of MT and FVB graft from the study, we that overexpression of MT reduced ROS in beta cells to many from ROS islet a nitric or to MT transgenic islets maintained islets syngeneic transplantation. MT islets by transplantation and MT reduced the of in islet of MT was due to from hypoxia due to of immune to many ROS transplantation and the of ROS or to beta cells it is that antioxidant many of ROS most antioxidant in and in the of ROS that and and superoxide is to of the provided by a antioxidant was the that protected islets from but provided from nitric MT broad antioxidant In MT to nitric radical superoxide radical radical and peroxynitrite We that MT was of these ROS in transgenic pancreatic islets and also that MT reduced and produced by nitric is considered to be an of beta cell produced by many of MT most ROS that MT overexpression a test of the of ROS in beta cell produced transplantation and overexpression was to the of by in to an of of improved graft that MT most the produced in the early of to immune rejection of the we that MT protected graft in syngeneic which is in the of immune many that to early graft that hypoxia is Islet an in syngeneic islets is O2). of oxygen islet cell and cell survival. that is a reduced oxygen and the of in and islets Islet to by by the of of cell produced by in hypoxia in the is MT was in ROS and cell produced by Because was from the of ROS have due to hypoxia or have to the of islet of and the islets overexpression of an of immune produced a of graft which was to be due to from immune We that MT produced a or greater of in in a direct of the of the is provided MT is and protected hypoxia, is and was to immune the of these of or the for islet transplantation. the for and islet transplantation. of is an in graft is MT improved islet by to that ROS for islet and be in islet graft In the study, we that overexpression of MT reduced ROS in beta cells to many from ROS islet a nitric or to MT transgenic islets maintained islets syngeneic transplantation. MT islets by transplantation and MT reduced the of in islet of MT was due to from hypoxia due to of immune to many ROS transplantation and the of ROS or to beta cells it is that antioxidant many of ROS most antioxidant in and in the of ROS that and and superoxide is to of the provided by a antioxidant was the that protected islets from but provided from nitric MT broad antioxidant In MT to nitric radical superoxide radical radical and peroxynitrite We that MT was of these ROS in transgenic pancreatic islets and also that MT reduced and produced by nitric is considered to be an of beta cell produced by many of MT most ROS that MT overexpression a test of the of ROS in beta cell produced transplantation and MT overexpression was to the of by in to an of of improved graft that MT most the produced in the early of to immune rejection of the we that MT protected graft in syngeneic which is in the of immune many that to early graft that hypoxia is Islet an in syngeneic islets is O2). of oxygen islet cell and cell survival. that is a reduced oxygen and the of in and islets Islet to by by the of of cell produced by in hypoxia in the is MT was in ROS and cell produced by Because was from the of ROS have due to hypoxia or have to the of islet of and the islets overexpression of an of immune produced a of graft which was to be due to from immune We that MT produced a or greater of in in a direct of the of the is provided MT is and protected hypoxia, is and was to immune the of these of or the for islet transplantation. the for and islet transplantation. of is an in graft is MT improved islet by to that ROS for islet and be in islet graft We for the